Karolinska Development
Karolinska Development AB is a venture capital firm based in Stockholm, Sweden, established in 2003. The firm specializes in early-stage investments in the life sciences and healthcare sectors, focusing on pharmaceutical research and development, biotechnology, medical technology, and related fields. Karolinska Development aims to create value by selecting commercially attractive medical innovations, developing them to enhance their return on investment, and subsequently commercializing these innovations through sales or out-licensing agreements. The firm primarily targets projects within the Nordic region, particularly in Sweden, and typically invests in up to five projects annually, often collaborating with innovators who serve as board members and advisors. With a structured selection process and a focus on minimizing operational costs in the initial stages, Karolinska Development seeks to advance its portfolio companies until they reach critical milestones for valuation increases. The firm prefers to exit investments at the Phase II stage of product development, which offers significant potential for successful negotiation of licensing or sales agreements.
Top Stages
Past deals in Nordic Europe
Modus Therapeutics
Post in 2025
Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.
Modus Therapeutics
Post in 2024
Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.
BOOST Pharma
Venture Round in 2024
BOOST Pharma is a biotechnology research company based in Copenhagen, Denmark, founded in 2019. The company specializes in developing a stem cell therapy aimed at treating osteogenesis imperfecta, a genetic disorder characterized by fragile bones. BOOST Pharma's innovative approach utilizes novel mesenchymal stem cells known for their strong bone-forming capabilities. Once injected into patients, these stem cells migrate to the bone, where they engraft and initiate the process of bone formation. This therapeutic strategy enables clinicians to address the disease at its earliest stages, potentially enhancing long-term outcomes for patients.
PharmNovo
Venture Round in 2023
PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.
Modus Therapeutics
Post in 2023
Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.
PharmNovo
Venture Round in 2022
PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.
Modus Therapeutics
Post in 2022
Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.
Forendo Pharma
Venture Round in 2018
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.
Forendo Pharma
Series A in 2014
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.
Forendo Pharma
Series A in 2013
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.
Asarina Pharma
Venture Round in 2011
Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.
Eribis Pharmaceuticals
Venture Round in 2010
Eribis Pharmaceuticals AB develops drugs for the treatment of cardiovascular disorders, primarily acute myocardial ischemia and surgical preconditioning. Myocardial ischaemia is the pathological loss of or reduction in blood flow to a part of the muscular tissue of the heart. The company offers peptides, which are used in cardio and tissue protection, antihypoxia, and analgesia. Eribis Pharmaceuticals AB was founded in 2006 and is based in Uppsala, Sweden.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.